PengXiaoMD
Anesthesiology • Boston, MAInstructor, Anaesthesia, Massachusetts General Hospital, Harvard Medical School
Are you Dr. Xiao?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 20 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
243 Charles St
Boston, MA 02114Phone+1 617-573-3380Fax+1 617-573-4033
Summary
- Dr. Peng Xiao, MD is a board certified anesthesiologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, West Virginia, and Pennsylvania. He is affiliated with Massachusetts General Hospital, Massachusetts Eye and Ear, and Tufts Medical Center.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Anesthesiology, 1998 - 2001
Icahn School of Medicine at Mount Sinai (New York Eye and Ear Infirmary at Mount Sinai)Residency, Surgery, 1997 - 1998
Suzhou Medical CollegeClass of 1982
Certifications & Licensure
MA State Medical License 2001 - 2025
WV State Medical License 2001 - 2025
PA State Medical License 1999 - 2001- American Board of Anesthesiology Anesthesiology
Publications & Presentations
PubMed
- 2 citationsA metabolic switch orchestrated by IL-18 and the cyclic dinucleotide cGAMP programs intestinal tolerance.Randall T Mertens, Aditya Misra, Peng Xiao, Seungbyn Baek, Joseph M Rone
Immunity. 2024-09-10 - 8 citationsImmunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.Devivasha Bordoloi, Peng Xiao, Hyeree Choi, Michelle Ho, Alfredo Perales-Puchalt
Genes & Cancer. 2021-01-01 - 1 citationsSynthetic DNA Delivery of an Engineered Arginase Enzyme Can Modulate Specific Immunity In Vivo.Makan Khoshnejad, Alfredo Perales-Puchalt, Yaya Dia, Peng Xiao, Ami Patel
Molecular Therapy. Methods & Clinical Development. 2020-09-11
Press Mentions
MBZUAI Welcomes Senior Delegation from Weizmann Institute in Abu DhabiMay 3rd, 2021- G42 and ONT Co-Develop Ultra-Scalable RNA Sequencing Based Solution for COVID-19 DetectionJune 11th, 2020
- UAE’s Group 42 and UK’s Oxford Nanopore Co-Develop Ultra-Scalable Solution for COVID-19 DetectionJune 9th, 2020
- Join now to see all
